Squarepoint’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Squarepoint’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1	Closed	-$46K	–	2145
2016 Q4	$46K	Buy	+1	New	+$89.4K	﹤0.01%	1702

Other funds holding NVIV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICM

IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's NVIV Position: Q1 2017 in Review

Squarepoint sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2017, closing a stake of 1 share — an estimated $46K sold.

Squarepoint first reported a position in NVIV in Q4 2016 and held it in 1 quarter. The position peaked at $46K in Q4 2016. 42 funds tracked by Wall St. Rank hold NVIV as of Q1 2017.

Squarepoint reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2017 after selling out during the quarter.
Squarepoint sold 1 InVivo Therapeutics Holdings Corp share in Q1 2017, an estimated $46K.
Squarepoint first reported a position in InVivo Therapeutics Holdings Corp in Q4 2016 and held it in 1 quarter.
Squarepoint's InVivo Therapeutics Holdings Corp position peaked at $46K in Q4 2016.
42 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2017.

Based on Squarepoint's 13F filing for Q1 2017, filed 15 May 2017.